Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hyun-Soo Lee

Dermatology Flushing, NY Medical Doctor

NPI 1558446674 CMS profile 206349

14472 Northern Blvd Ste 203, Flushing, NY 11354

Open in the dashboard

General payments

$16,592

874 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hyun-Soo Lee of Flushing, NY is reported in the CMS Open Payments database as having received $16,592 across 874 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,543 190
2024 General $3,569 178
2023 General $2,709 152
2022 General $1,936 101
2021 General $1,207 59
2020 General $1,268 68
2019 General $2,360 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hyun-Soo Lee
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Hyun-Soo Lee were reported at $3,543. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Hyun-Soo Lee Dermatology median Middle half National median
2019 $2,360 $454 $129–$1,240 $163
2020 $1,268 $235 $81–$756 $114
2021 $1,207 $377 $108–$1,108 $132
2022 $1,936 $514 $143–$1,391 $149
2023 $2,709 $607 $159–$1,674 $160
2024 $3,569 $751 $204–$1,903 $164
2025 $3,543 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,221 144 payments
  2. LEO Pharma Inc. $1,877 160 payments
  3. Janssen Biotech, Inc. $1,777 73 payments
  4. Pfizer Inc. $1,724 110 payments
  5. Novartis Pharmaceuticals Corporation $1,334 66 payments
  6. Genzyme Corporation $1,123 44 payments
  7. Lilly USA, LLC $862 54 payments
  8. Regeneron Healthcare Solutions, Inc. $768 30 payments
  9. E.R. Squibb & Sons, L.L.C. $733 25 payments
  10. Amgen Inc. $503 15 payments
  11. Other $3,669 153 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,829 863 payments
  2. Education $763 11 payments
Products named General payments · program years 2019–2025
  1. ADBRY $1,774 153 payments
  2. TREMFYA $1,719 70 payments
  3. EUCRISA $1,244 84 payments
  4. CIBINQO $1,098 66 payments
  5. DUPIXENT $1,079 37 payments
  6. SKYRIZI $1,069 63 payments
  7. LITFULO $884 51 payments
  8. TALTZ $768 49 payments
  9. SOTYKTU $733 25 payments
  10. COSENTYX $704 32 payments
  11. Other $8,202 393 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

4,392

Median for Dermatology: 534

Drug cost

$1,737,464

Median for Dermatology: $67,151

Branded share of claims

16.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 106 $400,266
Skyrizi Pen Risankizumab-Rzaa Brand 15 $304,233
Otezla Apremilast Brand 33 $167,066
Tremfya Guselkumab Brand 13 $163,522
Taltz Autoinjector Ixekizumab Brand 19 $136,204
Adbry Tralokinumab-Ldrm Brand 35 $128,951
Humira(Cf) Pen Adalimumab Brand 12 $127,265
Opzelura Ruxolitinib Phosphate Brand 41 $82,066
Xolair Omalizumab Brand 19 $48,665
Tacrolimus Generic 168 $32,258

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$143,135

Of which drugs: $1,526

Medicare patients

546

Average age 76

Services billed

2,982

274 women, 272 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 44%
Ischemic heart disease 27%
Osteoporosis 22%
Chronic kidney disease 17%
Cancer 17%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 32 95 $66

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADBRY
$470 35 —
DUPIXENT
$400 106 —
TREMFYA
$351 13 —
SOTYKTU
$335 — —
VTAMA
$268 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

874 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record